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Approximate Dynamic Programming and
Its Applications to the Design of Phase I
Cancer Trials
Jay Bartroff and Tze Leung Lai
Abstract. Optimal design of a Phase I cancer trial can be formulated
as a stochastic optimization problem. By making use of recent advances
in approximate dynamic programming to tackle the problem, we de-
velop an approximation of the Bayesian optimal design. The resulting
design is a convex combination of a “treatment” design, such as Babb
et al.’s (1998) escalation with overdose control, and a “learning” design,
such as Haines et al.’s (2003) c-optimal design, thus directly address-
ing the treatment versus experimentation dilemma inherent in Phase I
trials and providing a simple and intuitive design for clinical use. Com-
putational details are given and the proposed design is compared to
existing designs in a simulation study. The design can also be readily
modified to include a first stage that cautiously escalates doses similarly
to traditional nonparametric step-up/down schemes, while validating
the Bayesian parametric model for the efficient model-based design in
the second stage.
Key words and phrases: Dynamic programming, maximum tolerated
dose, Monte Carlo, rollout, stochastic optimization
1. INTRODUCTION
In typical Phase I studies in the development of
relatively benign drugs, the drug is initiated at low
doses and subsequently escalated to show safety at
a level where some positive response occurs, and
healthy volunteers are used as study subjects. This
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paradigm does not work for diseases like cancer, for
which a non-negligible probability of severe toxic re-
action has to be accepted to give the patient some
chance of a favorable response to the treatment.
Moreover, in many such situations, the benefits of
a new therapy may not be known for a long time
after enrollment, but toxicities manifest themselves
in a relatively short time period. Therefore, patients
(rather than healthy volunteers) are used as study
subjects, and given the hoped-for (rather than ob-
served) benefit for them, one aims at an acceptable
level of toxic response in determining the dose. Cur-
rent designs for Phase I cancer trials, which are se-
quential in nature, are an ad hoc attempt to rec-
oncile the objective of finding a maximum tolerated
dose (MTD) with stringent ethical demands for pro-
tecting the study subjects from toxicities in excess
of what they can tolerate. It treats groups of three
patients sequentially, starting with the smallest of
an ordered set of doses. Escalation occurs if no tox-
icity is observed in all three patients; otherwise an
1
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additional three patients are treated at the same
dose level. If only one of the six patients has toxic-
ity, escalation again continues; otherwise the trial
stops, with the lower dose declared as MTD. As
pointed out by Storer (1989), these designs, com-
monly referred to as 3-plus-3 designs, are difficult
to analyze, since even a strict quantitative defini-
tion of MTD is lacking, “although it should be taken
to mean some percentile of a tolerance distribution
with respect to some objective definition of clinical
toxicity,” and the “implicitly intended” percentile
seems to be the 33rd percentile (related to 2/6).
Storer (1989) also considered three other “up-and-
down” sequential designs for quantile estimation in
the bioassay literature and performed simulation
studies of their performance in estimating the 33rd
percentile. Subsequent simulation studies by
O’Quigley et al. (1990) showed the performance of
these designs to be “dismal,” for which they pro-
vided the following explanation: “Not only do (these
designs) not make efficient use of accumulated data,
they make use of no such data at all, beyond say the
previous three, or sometimes six, responses.” They
proposed an alternative design, called the continual
reassessment method (CRM), which uses paramet-
ric modeling of the dose–response relationship and
a Bayesian approach to estimate the MTD or, more
generally, the dose level x such that the probability
F (x) of a toxic event is p (1/3 in the case of MTD).
Letting θ = (α,β)′ and assuming the usual logistic
model
Fθ(x) = 1/{1 + e
−(α+βx)}(1)
for the probability of a toxic response at dose level x,
the problem of optimal choice of n dose levels to esti-
mate the MTD seems to be covered by the theory of
nonlinear designs. A well-known difficulty in nonlin-
ear design theory is that the optimal design for pa-
rameter estimation involves the unknown parameter
vector. To circumvent the difficulty, it has been pro-
posed that the design be constructed sequentially,
using observations made to date to estimate θ by
maximum likelihood and choosing the next design
point by using the MLE to replace the unknown
parameter value in the optimal design; see Fedorov
(1972). If θ is known, then a target probability p
of response is attained at the level xθ that solves
Fθ(xθ) = p, that is, xθ = [log(p/(1− p))− α]/β. Wu
(1985) proposed to use at stage t+ 1 the certainty
equivalence (or plug-in) level x
θˆt
, where θ̂t is the
MLE of θ based on (xi, yi), 1≤ i≤ t, and yi is the
binary response at dose level xi. Using some approx-
imations, he also derived a recursive representation
of x
θˆt
and showed that it is asymptotically equiva-
lent (as t→∞) to the adaptive stochastic approx-
imation rule of Lai and Robbins (1979). The like-
lihood version of CRM proposed by O’Quigley and
Shen (1996) in response to the comments of Korn
et al. (1994) on Bayesian designs is in fact a variant
of Wu’s (1985) design. Babb et al. (1998) pointed
out that the symmetric nature of squared error loss
used by CRM may not be appropriate for modeling
the toxic response to a cancer treatment. They pro-
posed the escalation with overdose control (EWOC)
method, which uses an asymmetric linear loss func-
tion that penalizes dose level x=MTD+δ for δ > 0,
corresponding to an overdose, more than an under-
dose x=MTD− δ. Whereas CRM is equivalent to
estimating the MTD at each stage by the mean of
the posterior distribution of xθ, EWOC is equivalent
to estimating the MTD at each stage by the ωth
quantile of the posterior distribution of xθ, where
ω ∈ (0,1/2) is the so-called feasibility bound, usually
chosen to be slightly less than p. There has also been
much work on designs intended to give an accurate
post-experiment estimate of the MTD or other func-
tions of the unknown parameter vector θ. For exam-
ple, locally optimal designs such as c- andD-optimal
designs have been investigated extensively for bi-
nary responses, and because a nonlinear model’s in-
formation matrix for binary data is a function of
the unknown parameters, locally optimal designs are
usually applied using initial estimates, multistage
methods or Bayesian priors. Haines, Perevozskaya
and Rosenberger (2003) proposed a two-stage design
whose first stage is a locally optimal design based
on a chosen prior, which is then updated sequen-
tially during its second stage. A comparative study
of these methods is given in Section 4.
Since the parameter θ is unknown, active statisti-
cal learning involves setting the doses at levels that
give maximum information about the function of
the unknown parameters of interest, the MTD, and
how to do this is a problem in nonlinear experimen-
tal design theory (Abdelbasit and Plackett, 1983;
Dette et al., 2004). On the other hand, there is also
an ethical issue of treating patients in the Phase I
trial at dose levels below the unknown MTD for
safety, and hopefully close to the MTD for efficacy.
This dilemma between treatment of current patients
and efficient experimentation to gather information
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for future patients was articulated by Lai and Rob-
bins (1979) in a simple linear regression model yk =
α + βxk + εk, where, instead of the MTD, the de-
sired level is (y∗ − α)/β, for some given value y∗.
Whereas an asymptotic theory of how this dilemma
can be resolved optimally as n→∞ was developed
by Lai and Robbins (1979), it was quite recent that
a tractable scheme was developed by Han, Lai and
Spivakovsky (2006) to compute an approximately
optimal solution for finite sample size n (number of
patients enrolled in the trial).
In Section 2 we introduce a basic stochastic opti-
mization problem that incorporates the treatment
versus experimentation dilemma in the design of
Phase I cancer trials. This problem adopts a Bayesian
formulation as in CRM and EWOC, for which the
computation of the posterior distributions of the pa-
rameters and of the MTD is described in Section 2.
Because the regression function Fθ(x) =Eθ(y|x) for
the binary response y given by (1) is nonlinear in the
parameters, the stochastic optimization problem is
considerably more difficult than the linear regression
model E(y|x) = α+ βx considered by Lai and Rob-
bins (1979). We review in Section 2 recent advances
in the field of approximate dynamic programming,
which we use in Section 3 to develop a new tool for
tackling the stochastic optimization problem. Using
this tool, we derive nearly optimal hybrid designs in
Section 3. These hybrid designs are convex combina-
tions (and therefore hybrids) of designs that are tar-
geted toward treating the current patient at the best
guess of the MTD (e.g., EWOC and CRM) and the
Haines–Perevozskaya–Rosenberger designs that are
D- or c-optimal in estimating the model parameters
for future patients. The weights in these convex com-
binations are determined by approximate dynamic
programming and can be conveniently stored to pro-
vide simple table look-up schemes for the clinical
user, as noted in Section 5 which gives some conclud-
ing remarks. Section 4 provides a comparative study
of the hybrid design and previous designs. It also in-
troduces a modified hybrid design that incorporates
the traditional nonparametric step-up/down scheme
as a cautious first stage, followed by the model-based
design in the second stage of a Phase I cancer trial.
2. STOCHASTIC OPTIMIZATION RELATED
TO THE TREATMENT VERSUS
EXPERIMENTATION DILEMMA
To begin with, we specify a prior distribution on
θ by following Babb et al. (1998) who first specify a
range [xmin, xmax] of possible dose values believed to
contain the MTD, with xmin believed to be a conser-
vative starting value. Rather than directly specify-
ing the prior distribution π for the unknown param-
eter θ of the working model to be used in the second
stage, which may be hard for investigators to do in
practice, an upper bound q > 0 on the probability
ρ= Fθ(xmin) of toxicity at xmin can be elicited from
investigators; uniform distributions over [xmin, xmax]
and [0, q] are then taken as the prior distributions for
the MTD and Fθ(xmin), respectively. Let Fk denote
the information set generated by the first k doses
and responses, that is, by (x1, y1), . . . , (xk, yk). Let-
ting η denote the MTD, it is convenient to trans-
form from the unknown parameters (α,β) in the
two-parameter logistic model (1) to (ρ, η) via the
formulas
α=
xmin log(1/p− 1)− η log(1/ρ− 1)
η − xmin
,(2)
β =
log(1/ρ− 1)− log(1/p− 1)
η− xmin
,(3)
giving
α+ βx= ((x− η) log(1/ρ− 1)
− (x− xmin) log(1/p− 1))
(4)
/(η − xmin)
= ψ(x,ρ, η).
Assuming that the joint prior distribution of (ρ, η)
has density π(ρ, η) with support on [0, q]× [xmin, xmax],
the Fk-posterior distribution of (ρ, η) has density
f(ρ, η|Fk)
=C−1
k∏
i=1
[
1
1 + e−ψ(xi,ρ,η)
]yi
(5)
·
[
1
1 + eψ(xi,ρ,η)
]1−yi
π(ρ, η),
where
C =
∫ xmax
xmin
∫ q
0
k∏
i=1
[
1
1 + e−ψ(xi,ρ,η)
]yi
·
[
1
1 + eψ(xi,ρ,η)
]1−yi
× π(ρ, η)dρdη
is the normalizing constant. The marginal Fk-posterior
distribution of η is then
f(η|Fk) =
∫ q
0
f(ρ, η|Fk)dρ.(6)
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The aforementioned CRM and EWOC doses based
on Fk are the mean and the ω-quantile of (6).
2.1 A Global Risk Function and Its Minimization
Note that using EWOC or CRM amounts to the
“myopic” policy of dosing the (k + 1)th patient at
the dose xk+1 = x that minimizes E[h(x, η)|Fk ], in
which
h(x, η) =
 (x− η)
2 for CRM,
ω(η− x)+
+ (1− ω)(x− η)+ for EWOC,
(7)
where x+ =max(x,0) and
E[h(x, η)|Fk ] =
∫ xmax
xmin
h(x, η)f(η|Fk)dη.
Since the information about the dose–toxicity rela-
tionship gained from xk+1 and the response yk+1
affects the ability to safely and effectively dose the
other patients k+2, k+3, . . . , n, one potential weak-
ness of these myopic policies is that they may be
inadequate in generating information on θ for treat-
ing the rest of the patients, as well as the post-
experimental estimate of the MTD for subsequent
phases. To incorporate these considerations in a
Phase I trial, x1, x2, . . . , xn should be chosen sequen-
tially in such a way as to minimize the global risk
E
[
n∑
i=1
h(xi, η) + g(ηˆ, η)
]
,(8)
in which the expectation is taken over the joint dis-
tribution of (ρ, η;x1, y1, . . . , xn, yn). Note that (8)
measures the effect of the dose xk on the kth patient
through h(xk, η), its effect on future patients in the
trial through
∑n
i=k+1 h(xi, η), and its effect on the
post-trial estimate ηˆ through g(ηˆ, η). It can there-
fore be used to address the dilemma between safe
treatment of current patients in the study and effi-
cient experimentation to gather information about
η for future patients. As noted in Section 1, Lai and
Robbins (1979) have introduced a similar global risk
function to address the dilemma between informa-
tion and control in the choice of xk in the linear
regression model yk = α+ βxk + εk so that the out-
puts yk, 1≤ k ≤ n, are as close as possible to some
target value y∗. Specifically, they consider (8) with
g = 0 and h(x;α,β) = (α+ βx− y∗)2.
Dynamic programming is a standard approach to
a stochastic optimization problem of the form (8).
Define
hk(x) =

E[h(x, η)|Fk ], 0≤ k < n− 1,
E[h(x, η)
+ g(ηˆ(x1, . . . , xn−1, x), η)|Fn−1],
k = n− 1.
(9)
To minimize (8), dynamic programming solves for
the optimal design x∗1, . . . , x
∗
n by backward induction
that determines x∗k by minimizing
hk−1(x) +E
[
n∑
i=k+1
hi−1(x
∗
i )
∣∣∣Fk−1, xk = x
]
(10)
after determining the future dose levels x∗k+1, . . . , x
∗
n.
Note that (10) involves computing the conditional
expectation of
∑n
i=k+1 hi−1(x
∗
i , η) given the dose x
at stage k and the information set Fk−1, and that
x∗k is determined by minimizing such conditional ex-
pectation over all x. For i≥ k+1, since x∗i is a com-
plicated nonlinear function of the past observations
and of yk, x
∗
k+1, yk+1, . . . , x
∗
i−1, yi−1 that are not yet
observed, evaluation of the aforementioned condi-
tional expectation is a formidable task. To overcome
this difficulty, we use recent advances in approxi-
mate dynamic programming, which we first review
and then extend and modify for the problem of min-
imizing the global risk (8).
2.2 Rollout Algorithms
To begin with, consider the problem of minimiz-
ing (8) with g = 0 and h(x;α,β) = (α + βx − y∗)2
in the linear regression model yk = α + βxk + εk
with i.i.d. normal errors εi having mean 0. Assum-
ing a normal prior distribution of (α,β), the pos-
terior distribution of (α,β) given Fi−1 is also bi-
variate normal with parameters Ei−1(α),Ei−1(β),
Ei−1(α
2),Ei−1(β
2),Ei−1(α · β), in which Ei−1 de-
notes conditional expectation given Fi−1. These con-
ditional moments have explicit recursive formulas;
see Section 4 of Han, Lai and Spivakovsky (2006).
The myopic policy that chooses x at stage i to min-
imize E[(α+ βx− y∗)2|Fi−1] is given explicitly by
xˆi = Ei−1{(y
∗ −α)β}/Ei−1(β
2)
(11)
= {y∗Ei−1(β)−Ei−1(αβ)}/Ei−1(β
2).
Although the myopic policy is suboptimal for the
global risk function (8), Han, Lai and Spivakovsky
(2006) use it as a substitute for the intractable x∗i
for k + 1 ≤ i ≤ n in (10), in which the conditional
expectation can then be evaluated by Monte Carlo
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simulation. This method is called rollout in approx-
imate dynamic programming. The idea is to ap-
proximate the optimal policy x∗k by minimizing (10)
with x∗k+1, . . . , x
∗
n replaced by some known base pol-
icy xˆk+1, . . . , xˆn, which ideally is some easily com-
puted policy that is not far from the optimum. Specif-
ically, given a base policy xˆ = (xˆ1, . . . , xˆn), let xˆ
(1)
k
be the x that minimizes
hk−1(x) +E
[
n∑
i=k+1
hi−1(xˆi)
∣∣∣Fk−1, xˆk = x
]
,(12)
and the expectation in the second term in (12) is
typically evaluated by Monte Carlo simulation. The
policy xˆ(1) = (xˆ
(1)
1 , . . . , xˆ
(1)
n ) is called the rollout of
xˆ and has been used for stochastic control problems
arising in a variety of applications; see Section 2.1 of
Han, Lai and Spivakovsky (2006). The rollout xˆ(1)
may itself be used as a base policy, yielding xˆ(2), and,
in theory, this process may be repeated an arbitrary
number of times, yielding xˆ(1), xˆ(2), xˆ(3), . . . . Letting
R(x) =E[
∑n
i=1 hi−1(xi)], Bayard (1991) showed that,
regardless of the base policy, rolling out n times
yields the optimal design and that rolling out al-
ways improves the base design, that is, that
R(xˆ)≥R(xˆ(1))≥R(xˆ(2))≥ · · ·
(13)
≥R(xˆ(n)) =R(x∗)
for any policy xˆ, where x∗ denotes the optimal pol-
icy.
For the global risk function (8) associated with
Phase I designs, with h given by (7), one can use the
myopic design EWOC or CRM as the base design
in the rollout procedure. In contrast with the ex-
plicit formula (11) for the case of a linear regression
model with normal errors εt, the posterior distribu-
tion with density function (5) does not have finite-
dimensional sufficient statistics and the myopic de-
sign involves (a) bivariate numerical integration to
evaluate
E[hi(xi+1)|Fk−1, xk = x]
for i ≥ k, and (b) minimization of the conditional
expectation over x. The simulation studies in 4, in
which the rollout is implemented with EWOC as the
base design, show substantial improvements of the
rollout over EWOC and CRM. Although (13) says
that rolling out a base design can improve it and
rolling out n times yields the dynamic programming
solution, in practice, it is difficult to use a rollout
(which is defined by a backward induction algorithm
that involves Monte Carlo simulations followed by
numerical optimization at every stage) as the base
policy for another rollout. To overcome this diffi-
culty, we need a tractable representation of succes-
sive rollouts, which we develop by using other ideas
from approximate dynamic programming (ADP).
2.3 Combining Least Squares with Monte Carlo
in ADP
The conditional expectation in (10), as a func-
tion of x, is called the cost-to-go function in dy-
namic programming. An ADP method, which grew
out of the machine learning (or, more specifically, re-
inforcement learning) literature, is based on two sta-
tistical concepts concerning the conditional expec-
tation. First, for given x and the past information
Fk−1, the conditional expectation is an expectation
and therefore can be evaluated by Monte Carlo sim-
ulations, if one knows how hk(x
∗
k+1), . . . , hn−1(x
∗
n)
are generated. The second concept is that, by (9),
hi(xi+1) is a conditional expectation given Fi, which
is a regression function (or minimum-variance pre-
diction) of hi(xi+1), with regressors (or predictors)
generated from Fi. Based on a large sample (gener-
ated by Monte Carlo), the regression function can
be estimated by least squares using basis function
approximations, as is typically done in nonparamet-
ric regression. Combining least squares (LS) regres-
sion with Monte Carlo (MC) simulations yields the
following LS-MC method for Markov decision prob-
lems in reinforcement learning. Let {st, t ≥ 0} be
a Markov chain whose transition probabilities from
state st to st+1 depend on the action xt at time t,
and let ft(s,x) denote the cost function at time t, in-
curred when the state is s and the action x is taken.
Consider the statistical decision problem of choosing
x at each stage k to minimize the cost-to-go function
Qk(s,x)
=E
{
fk(s,x)(14)
+
n∑
t=k+1
ft(st, xt)
∣∣∣sk = s,xk = x
}
,
assuming that xk+1, . . . , xn have been determined.
Let
Vk(s) = min
x
Qk(s,x), x
∗
k = argmin
x
Qk(s,x).(15)
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These functions can be evaluated by the backward
induction algorithm of dynamic programming:
Vn(s) = minx fn(s,x), and for n> k ≥ 1,
Vk(s) = min
x
{fk(s,x)
(16)
+E[Vk+1(sk+1)|sk = s,xk = x]},
in which the minimizer yields x∗k. The LS-MCmethod
uses basis functions φj , 1 ≤ j ≤ J , to approximate
Vk+1 by V̂k+1 =
∑J
j=1 ak+1,jφj , and uses this ap-
proximation together with B Monte Carlo simula-
tions to approximate
E[Vk+1(sk+1)|sk = s,xk = x]
for every x in a grid of representative values. This
yields an approximation V˜k to Vk and also x̂k to x
∗
k.
Moreover, using the sample
{(sk,b, V˜k(sk,b)),1≤ b≤B}(17)
generated by the control action x̂k, we can perform
least squares regression of V˜k(sk,b) on (φ1(sk,b), . . . ,
φJ(sk,b)) to approximate V˜k by V̂k =
∑J
j=1 ak,jφj .
Further details of this approach can be found in
Chapter 6 of Bertsekas (2007).
Although the problem (10) can be viewed as a
Markov decision problem with the Ft+1-posterior
distribution being the state st, the state space of
the Markov chain at hand is infinite-dimensional,
consisting of all bivariate posterior distributions of
the unknown parameter vector (α,β). If the state
space were finite-dimensional, for example, Rm, then
one could approximate the value functions (15) by
commonly used basis functions in nonparametric re-
gression, such as regression splines and their ten-
sor products; see Hastie, Tibshirani and Friedman
(2001). However, in the infinite-dimensional case,
there is no such simple choice of basis functions
of posterior distributions, which are the states. As
pointed out in Section 6.7 of Bertsekas (2007), an al-
ternative to approximating the value functions Vk,
called approximation in value space, is to approxi-
mate the optimal policy by a parametric family of
policies so that the total cost can be optimized over
the parameter vector. This approach is called ap-
proximation in policy space and most of its literature
has focused on finite-state Markov decision prob-
lems and gradient-type optimization methods that
approximate the derivatives of the costs, as func-
tions of the parameter vector, by simulation. We
now describe a new method for approximation in
policy space, which uses iterated rollouts to opti-
mize the parameters in a suitably chosen parametric
family of policies.
The choice of the family of policies should involve
domain knowledge and reflect the kind of policies
that one would like to use for the actual applica-
tion. One would therefore start with a set of real-
valued basis functions of the state st of the Markov
chain with general, possibly infinitely-dimensional,
state space, on which the family of chosen policies
will be based. The control policies in this family can
be represented by πt(φ1(st), . . . , φm(st);β), which is
the action taken at time t [after st has been observed
and the basis functions φ1(st), . . . , φm(st) have been
evaluated] and in which β is a parameter to be cho-
sen iteratively by using successive rollouts, with
{πt(φ1(st), . . . , φm(st);β
(j)),1≤ t≤ n}
being the base policy for the rollout x(j+1). Using
the simulated sample
{(sk,b, x
(j+1)
k,b ),1≤ b≤B},
in which sk,b denotes the bth simulated replicate of
sk, least squares regression of x
(j+1)
k,b on πk(φ1(sk,b),
. . . , φm(sk,b);β) is performed to estimate β by β
(j+1);
nonlinear least squares is used if πk is nonlinear in β.
In view of (13), each iteration is expected to provide
improvements over the preceding one. A concrete
example of this method in a prototypical Phase I
setting is given in the next section, where linear re-
gression splines are used in iterated rollouts. In this
setting the state variable st represents the complete
treatment history up to time t in the trial—all prior
distributions, doses and responses up to that time—
and the cost function ft(st, x) will be replaced by
ht(x) given by (9).
3. HYBRID DESIGNS AS BASE POLICIES
FOR ITERATED ROLLOUTS
In their use of rollouts to approximate the opti-
mum for (8) for the normal model, Han, Lai and
Spivakovsky (2006), Section 3, used the structure of
their problem to come up with an ingenious “per-
turbation of the myopic rule” as a base policy to
improve the performance of the rollout, without per-
forming second- or higher-order rollouts. In this sec-
tion we explore this technique in the context of Phase I
designs, using such perturbations—called here hy-
brid designs—both as base policies and as a way to
represent highly complicated but efficient policies in
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a simple, clinically useful way. As pointed out in
Section 2.1, the objective function of the dynamic
programming problem (8) involves both experimen-
tation (for estimating the MTD) and treatment (for
the patients in the study). Consider the kth patient
in a trial of length n (≥ k). If the kth patient were
the last patient to be treated in the trial (n = k),
the best dose to give him/her would be the myopic
dose mk that minimizes hk−1(xk), given by (9). On
the other hand, early on in the trial, especially if
n − k is relatively large, one expects the optimal
dose to be perturbed from mk in the direction of
a dose that provides more information about the
dose–response model, for the relatively large num-
ber of doses that will have to be set for the future
patients. Since the optimal design theory for learn-
ing the MTD under overdose constraints, developed
by Haines, Perevozskaya and Rosenberger (2003),
yields a c- or D-optimal design ℓk, we propose to
use the following hybrid design representation of the
optimal dose sequence:
x∗k = (1− εk)mk + εkℓk,(18)
where ℓk is the chosen “learning design.” Of course,
any dosing policy admits the representation (18)
with
εk =
x∗k −mk
ℓk −mk
· 1{ℓk 6=mk}.
However, we will show that it is possible to use roll-
outs to choose εk of a simple form, not depending
on x∗k, such that the resulting hybrid design given
by the right-hand side of (18) is highly efficient.
Similar ideas have been used in “ε-greedy policies”
in reinforcement learning (Sutton and Barto, 1998,
page 122).
From our simulation studies that include the ex-
ample in Section 3.2, we have found that the sequen-
tial c-optimal design (Haines et al., 2003, Section 5)
with c being the vector (0,1)′ works well for learning
design ℓk in (18), which we now briefly explain. In
general, optimal designs such as c- and D-optimal
can be characterized as optimizing some convex loss
function Ψ of the information matrix I(θ, ξ) associ-
ated with the parameter value θ and a measure ξ on
the space of design points (see Fedorov, 1972). Here
(nI(θ, ξ))−1 is interpreted as the asymptotic vari-
ance of the MLE θ̂n of θ. The optimization problem
can be generalized to the sequential Bayes setting,
with prior distribution π on θ, by finding the ξ that
minimizes∫
Ψ[I(θ, ξk−1) + I(θ, ξ)]π(θ|Fk−1)dθ(19)
at the kth stage, where ξk−1 is the empirical measure
of the previous design points. In the case k = 1, (19)
is replaced by
∫
Ψ[I(θ, ξ)]π(θ)dθ. For a given vec-
tor c, the c-optimal design measure ξ minimizes the
asymptotic variance of the linear estimator c′θ̂n of
c′θ or, equivalently, Ψ[I(θ, ξ)] = c′(I(θ, ξ))−1c. Tak-
ing the Bayesian c-optimal design with c= (0,1)′ as
the learning design ℓk in (18) gives c
′θ = c′(α,β)′ =
β, hence, this design is optimal, in some sense, for
learning about β or, equivalently, about the slope
∂
∂x
E(y|x)
∣∣∣∣
x=η
=
∂
∂x
(
1
1 + e−(α+βx)
)∣∣∣∣
x=η
= βp(1− p)
of the dose response curve (1) at the MTD, for which
p is 1/3 or some other prespecified value. This has
the following connections to the stochastic optimiza-
tion problem of Lai and Robbins (1979) discussed in
Section 1 and to the rollout procedure of Han, Lai
and Spivakovsky (2006). For the normal model dis-
cussed in Section 1 and as an asymptotic limiting
case of other models, Sacks (1958) showed that the
optimal value of the step size (a user-supplied pa-
rameter in the Lai–Robbins procedure affecting its
convergence rate) is proportional to (∂/∂x)E(y|x).
Moreover, Han, Lai and Spivakovsky (2006), Sec-
tion 3, found that in the normal model, perturba-
tions of the myopic policy in the direction of this
c-optimal design provide a base design for a rollout
that has comparable performance to that of an “or-
acle policy.”
3.1 Relating εk to the Uncertainty in the Bayes
Estimate E(η|Fk−1)
Since the treatment versus experimentation
dilemma discussed in Section 2 stems from the un-
certainty in the current estimate of the MTD η, it is
natural to expect that the amount of perturbation
from the myopic dose mk depends on the degree
of such uncertainty, using little perturbation when
the posterior distribution of η is peaked, and much
more perturbation when it is spread out. This sug-
gests choosing εk as a function of the posterior vari-
ance ν2k−1 =Var(η|Fk−1), whose reciprocal is called
the “precision” of E(η|Fk−1) in Bayesian parlance.
Following the approach described in Section 2.3, we
use functions of sk = νk−1/ν0 as basic features of
the posterior distribution of η to approximate the
εk in (18).
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To begin, Monte Carlo simulations are performed
to obtain the rollout x(1) of EWOC, yielding a sim-
ulated sample {(ek,b, sk,b), 1≤ b≤B}, where ek,b is
the bth simulated replicate of
ek =
x
(1)
k −mk
ℓk −mk
· 1{ℓk 6=mk},(20)
which is essentially the same as (18) with (x∗k, εk) re-
placed by (x
(1)
k , ek). The basic idea in Section 2.3 can
be implemented via nonparametric regression of ek,b
on sk,b, yielding the estimated regression function
gk. Letting êk = gk(sk), the hybrid design xk = (1−
êk)mk + êkℓk can then be used as the base policy to
form the rollout x(2), and this procedure can be re-
peated to obtain the iterated rollouts x(3),x(4), . . . .
Linear regression splines, and their tensor prod-
ucts for multivariate regressors, provide a convenient
choice of basis functions; see Section 9.4 of Hastie,
Tibshirani and Friedman (2001). For the present
problem, it suffices to use a truncated linear function
gk(s) =min{1, (β
(0)
k + β
(1)
k s)
+}
(21)
for s∗ ≤ s≤ s
∗,
where s∗ and s
∗ are the minimum and maximum
of the sample values sk,b, 1≤ b≤B, and to extend
beyond the range [s∗, s
∗] by
gk(s) =
{
sgk(s∗)/s∗, 0≤ s≤ s∗,
gk(s
∗), s≥ s∗,
(22)
which agrees with the constraint gk(0) = 0 and en-
sures that the weight assigned to experimentation
does not exceed gk(s
∗). A further simplification is
to group the data into K blocks so that εk = εk(s)
does not vary with k within each block, since it is
expected that the amount of experimentation for
the initial stages depends mostly on the uncertainty
about η, while for the final stages experimentation
would only benefit the post-trial estimate of η.
3.2 Example and Simulation Study
We illustrate the method in Section 3.1 by apply-
ing it to the following example, in which n= 10 and
[xmin, xmax] is transformed to [0,1] by location and
scale changes. Independent uniform priors on [0, q]
and [0,1] are used for ρ = Fθ(xmin) and the MTD
η, respectively; see (2) and (3) and the sentence fol-
lowing it. We use q = 1/3 and the EWOC loss with
ω = 1/4 in (7), and the squared error loss g(η̂, η) =
(η̂−η)2 in (8). Since n is relatively small, we can as-
sume for simplicity that (β
(0)
k , β
(1)
k ) in (21) does not
vary with k and estimate the common (β(0), β(1)) by
applying least squares regression to the sample
{(ek,b, sk,b) : 1≤ k ≤ n,1≤ b≤B}.
We also simply use (21) for all s without perform-
ing the extrapolation beyond [s∗, s
∗]. Rolling out
EWOC as the base design and using B = 2000 sim-
ulations, the preceding procedure gave (β(0), β(1)) =
(0.096,0.02). Putting
εk =min{1, (0.096 + 0.02νk−1/ν0)
+}(23)
in the hybrid design
x
(1)
k = (1− εk)mk + εkℓk,(24)
we used x(1) as the base policy of a second roll-
out, for which the preceding procedure yielded (β(0),
β(1)) = (−0.72,0.94). Here we used the sequential c-
optimal design with c= [0,1]′ as the learning design
ℓk (see Section 3). Table 1 contains the operating
characteristics, explained below, of EWOC and its
rollout, the first hybrid design x(1) with εk given
by (23) and the second hybrid design x(2) in which
(0.096,0.02) in (23) is replaced by (−0.72,0.94). Each
result is based on 2000 simulation runs. The val-
ues of (ρ, η) were generated from the prior distri-
bution given by the joint uniform distribution on
[0, q] × [xmin, xmax]. Figure 1 plots the cumulative
risk Rk =
∑k
i=1E[hi−1(xi)] of the EWOC, rollout
and hybrid designs for k = 1, . . . , n(= 10). The oper-
ating characteristics in Table 1 are the Monte Carlo
estimates of overall risk R10, the bias and root mean
squared error (RMSE) of the terminal MTD esti-
mate η̂10, the DLT rate P (y = 1) and the overdose
rate OD, which is the expected proportion of pa-
tients treated at doses higher than η. Standard er-
rors are given in parentheses.
The first hybrid design, which is an approxima-
tion to the rollout design, provides more than 10%
improvement in terminal risk R10 over the myopic
policy. The second hybrid design provides an ad-
ditional 5% improvement in the terminal risk R10,
and also smaller values of the DLT and OD rates
than the rollout design. The Monte Carlo simula-
tions used to evaluate the operating characteristics
and to fit the hybrid designs were performed by us-
ing rejection sampling to simulate from the poste-
rior distribution. At each stage, the posterior dis-
tribution of (ρ, η) is continuous and supported on
the compact set [0, q]× [xmin, xmax], hence, the joint
uniform distribution on [0, q]× [xmin, xmax] is a nat-
ural candidate for the instrumental distribution in
rejection sampling; see also the last paragraph of
Section 5.
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Table 1
Risk, bias and RMSE of the final MTD estimate, DLT rate and overdose rate (OD) of
EWOC, rollout (ROLL) of EWOC, and 1st and 2nd hybrid approximations
Design Risk Bias RMSE DLT OD
EWOC 0.84 (0.01) −0.20 (0.010) 0.31 (0.04) 29.8% (0.7%) 21.9% (0.6%)
ROLL 0.75 (0.01) −0.04 (0.009) 0.22 (0.03) 33.0% (0.7%) 31.2% (0.7%)
Hybrid 1 0.75 (0.02) −0.14 (0.012) 0.29 (0.06) 33.5% (1.5%) 37.5% (1.5%)
Hybrid 2 0.71 (0.01) −0.04 (0.005) 0.22 (0.04) 31.24% (0.9%) 27.8% (0.9%)
Fig. 1. Risk for EWOC, rollout of EWOC and hybrid designs.
4. A TWO-STAGE MODIFICATION AND
COMPARATIVE STUDY
Babb et al. (1998) used EWOC to design a Phase I
trial to determine the MTD, with p= 1/3, of the an-
timetabolite 5-fluorouracil (5-FU) for the treatment
of solid tumors in the colon, when taken in conjunc-
tion with fixed levels of the agents leucovorin (20
mg/m2) and topotecan (0.5 mg/m2). In this set-
ting, a toxicity is considered a grade 4 hematologic
or grade 3 or 4 nonhematologic toxicity within 2
weeks. As mentioned above, EWOC involves speci-
fying pre-trial a set
xmin = λ1 < λ2 < · · · ≤ xmax(25)
of possible dose values believed to contain the MTD,
where xmin is taken as the starting value. Based
on preliminary studies of 5-FU given in conjunction
with topotecan, a dose of xmin = 140 mg/m
2 of 5-FU
was believed to be safe when given with 0.5 mg/m2
of topotecan. Also, a previous trial concluded that
the MTD of 5-FU was 425 mg/m2 when admin-
istered without topotecan, so xmax was taken to
be 425 mg/m2 since 5-FU has been observed to be
more toxic when given with topotecan than alone.
The two-parameter logistic model (1) was chosen
based on previous experience with the agents, and
uniform prior distributions over [xmin, xmax] and
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[0,0.2] were chosen for the MTD and the proba-
bility Fθ(xmin), respectively. A feasibility bound of
ω = 0.25 was chosen for EWOC and p = 1/3. We
compare EWOC and other previous designs with
the rollout (abbreviated by ROLL) of EWOC and
the Hybrid 1 design described in Section 3.2 in this
setting with n= 24.
To give a feel for the computational time required
for the EWOC, ROLL and Hybrid 1 designs, on a
desktop personal computer with a 2.66 GHz pro-
cessor, the simulation of a single n= 24 run of the
ROLL design with the EWOC base design took 49
minutes, whereas the Hybrid 1 design took 0.4 sec-
onds and EWOC took 0.12 seconds. The Hybrid 1
design is computationally much simpler than ROLL
since it does not perform rollouts of a base design,
but rather calculates its dose via (24), where mk is
the EWOC dose and ℓk is the sequential c-optimal
learning design. So although the interpolation func-
tion (23) is derived from data gathered by ROLL
during its rollouts as described in 3, the Hybrid 1 de-
sign has computational time on the order of EWOC
and the learning design ℓk, even though the compu-
tational time required for ROLL is large.
4.1 A Comparative Study
Table 2 first lists Bayesian designs, followed by
non-Bayesian designs that include Wu’s (1985) de-
sign, stochastic approximation (Lai and Robbins,
1979) and two 3-plus-3 dose escalation designs. The
first 3-plus-3, denoted by 3+310, uses 10 uniformly-
spaced dose levels in [xmin, xmax] = [140,425]. The
second uses 20 uniformly-spaced dose levels and is
denoted by 3 + 320. Besides EWOC and its rollout
ROLL, the Bayesian designs include CRM, the con-
strained D-optimal design (abbreviated by D-opt)
of Haines et al. (2003) with constraint ε= 0.05 and
the unconstrained sequential Bayesian c-optimal de-
sign (abbreviated by c-opt) with c being the vector
(0,1)T. The prior density is assumed to be uniform:
π(ρ, η) = [q(xmax − xmin)]
−1
(26)
· 1{(ρ, η) ∈ [0, q]× [xmin, xmax]}
with q = 0.2, where 1(A) denotes the indicator of a
set A. The values of (ρ, η) were generated from the
prior distribution (26).
The performance of these designs is first evaluated
in terms of the global risk (8), in which we use the
squared error g(η̂, η) = (η̂ − η)2 for the MTD esti-
mate η̂ = η̂(xi, yi, . . . , xn, yn). We then evaluate per-
formance exclusively in terms of the bias and root
mean squared error (RMSE) of η̂ without taking
into consideration the risk to current patients, not-
ing that the c- and D-optimal designs focus on er-
rors of post-trial parameter estimates. Finally, since
safety of the patients in the trial is the primary con-
cern of traditional 3-plus-3 designs, performance is
also evaluated in terms of the DLT rate and the
probability of overdose (i.e., dose level exceeding the
MTD). Each result in Table 2 is based on 2000 sim-
ulations.
The results in Table 2 show that the effects of con-
sidering the “future” patients is large, with ROLL
and Hybrid 1 substantially reducing the global risk
from the myopic designs: in the case of ROLL, about
30% from EWOC, 35% from CRM, and more from
the 3-plus-3, c- and D-opt, SA and Wu designs. Al-
though ROLL has somewhat smaller global risk than
Hybrid 1, it is computationally much more expen-
sive, as noted above. The results for the 3-plus-3
designs show that they are highly sensitive to the
choice of λ1, λ2, . . . in (25). The 3+310 design, using
10 uniformly-spaced levels in [xmin, xmax], performs
perhaps surprisingly well, as it even has smaller risk
than D-opt, which suffers from substantial under-
dosing due to its overdose constraint of ε = 0.05.
This seems to be because the number 10 of dose lev-
els was a fortuitous choice given the parameter val-
ues and sample size of this study, allowing the 3+310
design to escalate to near the MTD in most cases.
However, there is often little information about the
appropriate number of doses and scale before a
Phase I cancer trial begins, and when dose levels
are chosen over a less fortuitous range or on too
fine a scale, as with the 3 + 320 design, the major-
ity of doses can end up being administered at levels
far below the therapeutic range near the MTD. We
emphasize that all of these designs are being evalu-
ated using the EWOC loss function in (7) which, in
particular for CRM, differs from its associated loss
function; using the CRM loss function in (7) results
in CRM having smaller global risk than EWOC,
but again ROLL (with CRM as its base design)
yields smaller global risk than both and the rela-
tionship between the other designs remains roughly
unchanged.
In terms of MTD estimation accuracy, CRM and
Wu have the smallest RMSE, closely followed by c-
opt and ROLL; CRM and Wu also have the small-
est absolute bias. It is interesting to note that the
designs which explicitly account for the asymmet-
ric underdose/overdose relationship, that is, ROLL,
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Table 2
Risk, bias and RMSE of the final MTD estimate, DLT rate and MTD overdose rate (OD), with SEs in parentheses, of
various designs
Design Risk Bias RMSE DLT OD
ROLL 0.81 (0.01) −0.069 (0.002) 0.126 (0.022) 27.68% (1.70%) 29.17% (1.87%)
Hybrid 1 0.92 (0.03) −0.075 (0.003) 0.128 (0.028) 24.68% (0.86%) 23.48% (0.68%)
EWOC 1.13 (0.01) −0.076 (0.003) 0.138 (0.024) 26.17% (0.98%) 19.69% (0.89%)
CRM 1.65 (0.01) 0.037 (0.003) 0.118 (0.021) 36.37% (1.10%) 62.69% (1.10%)
c-opt 1.71 (0.01) 0.060 (0.003) 0.126 (0.022) 23.44% (0.95%) 12.42% (0.74%)
D-opt 1.96 (0.02) −0.084 (0.006) 0.143 (0.023) 13.55% (0.31%) 3.78% (0.17%)
Wu 1.77 (0.04) 0.038 (0.009) 0.122 (0.045) 23.40% (0.54%) 40.25% (0.77%)
SA 1.52 (0.02) 0.063 (0.003) 0.131 (0.022) 22.39% (0.93%) 35.56% (0.40%)
3+ 310 1.87 (0.01) 0.060 (0.003) 0.138 (0.024) 17.06% (0.84%) 0.85% (0.21%)
3+ 320 2.19 (0.02) 0.070 (0.002) 0.161 (0.025) 14.11% (0.81%) 0.75% (0.29%)
Fig. 2. The first five dose levels given by EWOC, ROLL (in italics) and Hybrid 1 (in bold) in the 5-FU trial.
EWOC andD-opt (through its overdose constraint ε),
are negatively biased, while the others all have pos-
itive bias.
In terms of safety, D-opt and the 3 + 3 designs
have the smallest DLT and OD rates, but in view
of their large risk values, this safety comes at the
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cost of low doses that are nontherapeutic. CRM
has high estimation accuracy and moderate risk,
but also the largest DLT and OD rates because of
its symmetric loss function. The remaining designs,
ROLL, EWOC, Wu and SA, all have comparable
DLT and OD rates, but their risk values suggest
that the magnitude of the overdoses in Wu and SA
are larger than EWOC, which, in turn, has larger
overdoses than ROLL.
Of particular concern in phase I trials is coherence
of the design (Cheung, 2005), that is, whether the
next patient will be given a higher dose if the current
patient experiences a toxicity, and a lower dose if the
current patient does not. While a theoretical inves-
tigation of the coherence of the ROLL and Hybrid
designs is beyond our scope here, as an illustrative
example Figure 2 lists the first five doses given by
EWOC, ROLL and Hybrid 1 in the 5-FU trial set-
ting, assuming a nontoxic response to the first dose
of xmin = 140. Note that coherence is exhibited by
all three designs in this example.
4.2 A Two-Stage Design
When one may have concerns about the validity of
the Bayesian parametric model in this model-based
approach, one can readily incorporate the hybrid de-
signs as the second stage of a two-stage design. The
first stage of such escalates the doses cautiously by
using a modified 3-plus-3 design. For the batches
of 3 in the 3-plus-3 design, we propose to combine
the nonparametric step-up/down approach with a
parametric model-based dose determining scheme,
thereby checking the parametric model to be used
for model-based escalation in the second stage. This
modification of the traditional 3-plus-3 design uses a
specified set of dose levels (25). Set d1 = λ1 = xmin.
In the kth group of 3 patients, 2 patients are treated
at the same dose dk = λj and 1 patient at the EWOC
dose mk, computed given the doses and responses of
the previous 3(k − 1) patients. If no DLT occurs in
the group of 3 patients, dk+1 is increased to λj+1. If
1 DLT occurs, dk+1 stays the same at dk = λj . Oth-
erwise, 2 or 3 DLTS have occurred, so the trial is
stopped if dk = xmin, and otherwise continues with
dk+1 lowered to λj−1. (Alternatively, it may be de-
sired to stop when 3 toxicities occur, regardless of
what dk was.) The EWOC dose mk+1 is updated
when the process is repeated with the next group
of 3 patients. This process repeats until a certain
fraction of the total number n of patients has been
treated, provided the trial has not been stopped at
the first stage due to excess toxicities. We have found
from our simulation studies that switch-over points
around n/3 or n/4 seem to strike a balance between
enough time for conservative dose escalation and
model checking during the first stage, while leav-
ing enough time for efficient dose escalation in the
second stage.
The benefit of a first stage of conservative dose
escalation occurs when, unlike in Table 2, the prior
distribution of the MTD is misspecified. For exam-
ple, if the true MTD falls in the left tail of the prior
distribution of η, then the prior information about
the MTD is biased upward, which can cause over-
doses. In this situation, including an initial stage of
modified dose escalation, like the modified 3-plus-
3 scheme, provides additional safety by refining the
prior to be more accurate when it begins to be used
in the second stage. Focusing on the CRM, EWOC,
ROLL and Hybrid 1 designs, Table 3 contains the
results of a simulation study that considers a sit-
uation such as this, where the true MTD is the
lower 15th percentile of the MTD’s nominal uniform
prior distribution on [xmin, xmax]. That is, the data
are generated with η fixed at the 15th percentile of
[xmin, xmax] and ρ uniformly distributed over [0, q],
with q = 0.2 as in Table 2. The nominal prior for
(ρ, η) used by the Bayesian procedures in Table 3
is (26), the same as in Table 2, as are the values
of the other parameters. To see the effects of the
first stage of more conservative dose escalation, the
operating characteristics of ROLL are recomputed
using a first stage of length n/4 = 6; the dose lev-
els (25) used by the modified 3-plus-3 design are 10
uniformly-spaced levels in [xmin, xmax] = [140,425].
Adding this first stage to ROLL or Hybrid 1 sub-
stantially reduces the risk, DLT and overdose rates,
as shown in Table 3, in which (a) refers to the case
of n= 24 dose levels without the modified 3-plus-3
first stage, and (b) refers to the two-stage design us-
ing a first stage of length n/4 = 6 consisting of the
modified 3-plus-3 design.
5. CONCLUSION
Despite their shortcomings and the development
of alternative Bayesian approaches since 1990, con-
ventional dose-escalation designs are still widely used
in Phase I cancer trials because of the ethical is-
sue of safe treatment of patients currently in the
trial. However, a Phase I design also has the goal
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Table 3
Risk, bias and RMSE of the final MTD estimate, DLT rate and MTD overdose rate (OD), with SEs in parentheses, of
various designs with the MTD fixed at the lower 15th percentile of the misspecified prior
Design Risk Bias RMSE DLT OD
ROLL (a) 1.64 (0.02) −0.031 (0.003) 0.142 (0.025) 30.32% (1.03%) 39.38% (1.09%)
(b) 1.39 (0.02) −0.025 (0.003) 0.145 (0.026) 27.41% (1.00%) 33.39% (1.05%)
Hybrid 1 (a) 1.82 (0.05) −0.032 (0.002) 0.151 (0.027) 36.90% (1.52%) 42.31% (1.56%)
(b) 1.69 (0.04) −0.027 (0.003) 0.131 (0.036) 35.70% (1.51%) 41.11% (1.56%)
EWOC 2.29 (0.02) −0.034 (0.003) 0.155 (0.028) 35.33% (1.07%) 45.98% (1.11%)
CRM 3.83 (0.02) 0.037 (0.004) 0.179 (0.032) 44.18% (1.11%) 65.12% (1.07%)
of determining the MTD for a future Phase II can-
cer trial, and needs an informative experimental de-
sign to meet this goal. Von Hoff and Turner (1991)
have documented that the overall response rates in
Phase I trials are low and that substantial num-
bers of patients are treated at doses that are retro-
spectively found to be nontherapeutic. Eisenhauer
et al. (2000), page 685, have pointed out that “with
a plethora of molecularly defined antitumor targets
and an increasingly clear description of tumor biol-
ogy, there are now more antitumor candidate ther-
apies requiring Phase I study than ever,” and that
“unless more efficient approaches are undertaken,
Phase I trials may be a rate-limiting step in the pro-
cess of evaluation of novel anticancer agents.” The
hybrid designs in the previous section were moti-
vated by developing one such “more efficient” ap-
proach.
Hybrid designs with simple interpolation functions,
refined through iterated rollouts and regression, can
be implemented by using simple look-up tables for
the parameters in (21), and thus can be relatively
simple to use for clinicians. Given computer pack-
ages to compute the standard myopic and learning
designs, practitioners can use a look-up table for the
values εk in (18) as a function of the relative poste-
rior standard deviation νk−1/ν0. For given values of
the prior parameters xmin, xmax, p, q and ω, a com-
puter package can generate this look-up table, which
can be used at every stage of the trial. We are in the
process of developing open source software for this
purpose.
Tighiouart, Rogatko and Babb (2005) have shown
how Markov chain Monte Carlo (MCMC) can be
used to compute the posterior distribution of (ρ, η)
when the prior distribution is supported on [0, q]×
[xmin,∞), extending the model considered above
where the support of η is bounded above by xmax.
They note that priors in this class with a negative
correlation structure between ρ and η result in an
EWOC design with comparable accuracy for esti-
mating the MTD but lower DLT and OD rates,
relative to its performance for priors supported on
[0, q] × [xmin, xmax]. As noted in Section 4, a two-
stage design can easily address the higher DLT and
OD rates caused by misspecifications of such pri-
ors. On the other hand, even without a cautious
first stage, the above and other generalizations of
the prior of (ρ, η) can be seamlessly incorporated
into our hybrid design. In fact, the model M4 of
Tighiouart et al. (2005), which has been shown to
perform well in their simulation studies, has a left-
truncated, hierarchical normal prior distribution on
η, so the rejection sampling approach in the last
paragraph of Section 3.2 can be applied here by us-
ing, say, the exponential distribution as the instru-
mental distribution, since its tails are upper bounds
of those of the normal distribution. We can there-
fore still use the Monte Carlo approach laid out at
the end of Section 3.2.
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